A complex structure that includes isoquinolines joined by a cyclic ester; it is a DNA-binding agent and guanine N2 alkylator derived from the marine tunicate, Ecteinascidia turbinata. Trabectedin is used for the treatment of advanced soft-tissue SARCOMA, after failure of ANTHRACYCLINES or IFOSFAMIDE drug therapy.
Trabectedin has been studied across 11 research domains including 🔬 Oncology, 🧬 Hormones, 🫁 Liver & Detox, 🔬 Inflammation, 🛡️ Immunity. The primary research focus is 🔬 Oncology with 64% of studies addressing this area.
The following compounds share molecular targets with Trabectedin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Trabectedin is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.